ALZpath, Inc. announced a licensing agreement with Siemens Healthineers for use of its proprietary pTau217 antibody in the development of a pTau217 assay in the expanding menu of Siemens Healthineers in vitro diagnostic (IVD) tests for Alzheimer’s disease. The test is being designed for use on Siemens Healthineers’ Atellica immunoassay systems.
Blood-based neurodegenerative disease diagnostics, including those for Alzheimer’s, are a transformative advancement. The ALZpath pTau217 antibody has shown exceptional performance across a range of platforms to help identify patients with Alzheimer’s disease through a simple blood draw. It enables sensitive, accurate detection of Alzheimer’s disease pathology with performance comparable to PET imaging and cerebrospinal fluid (CSF) testing—and, via in vitro diagnostic tests, it may be deployed in a wide range of clinical settings. ALZpath’s pTau217 antibody is supported by robust clinical evidence, including more than 90 peer-reviewed studies.
As disease-modifying therapies reach broader use, scalable and accessible diagnostic tools are helping identify patients earlier in their disease.
